Logo image of ADCT

ADC THERAPEUTICS SA (ADCT) Stock Price, Quote, News and Overview

NYSE:ADCT - New York Stock Exchange, Inc. - CH0499880968 - Common Stock - Currency: USD

1.63  -0.04 (-2.4%)

After market: 1.63 0 (0%)

ADCT Quote, Performance and Key Statistics

ADC THERAPEUTICS SA

NYSE:ADCT (2/21/2025, 8:04:00 PM)

After market: 1.63 0 (0%)

1.63

-0.04 (-2.4%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High5.38
52 Week Low1.39
Market Cap157.60M
Shares96.69M
Float72.20M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-13 2025-03-13/amc
IPO05-15 2020-05-15


ADCT short term performance overview.The bars show the price performance of ADCT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40

ADCT long term performance overview.The bars show the price performance of ADCT in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ADCT is 1.63 USD. In the past month the price decreased by -7.39%. In the past year, price decreased by -65.17%.

ADC THERAPEUTICS SA / ADCT Daily stock chart

ADCT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About ADCT

Company Profile

ADCT logo image ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 273 full-time employees. The company went IPO on 2020-05-15. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

Company Info

ADC THERAPEUTICS SA

Biopole, route de la Corniche 3B

Epalinges VAUD 1066 CH

CEO: Christopher Martin

Employees: 274

Company Website: https://adctherapeutics.com/

Investor Relations: https://ir.adctherapeutics.com/

Phone: 41216530200

ADC THERAPEUTICS SA / ADCT FAQ

What is the stock price of ADC THERAPEUTICS SA today?

The current stock price of ADCT is 1.63 USD. The price decreased by -2.4% in the last trading session.


What is the ticker symbol for ADC THERAPEUTICS SA stock?

The exchange symbol of ADC THERAPEUTICS SA is ADCT and it is listed on the New York Stock Exchange, Inc. exchange.


On which exchange is ADCT stock listed?

ADCT stock is listed on the New York Stock Exchange, Inc. exchange.


What is the price forecast or stock price prediction for ADC THERAPEUTICS SA stock?

13 analysts have analysed ADCT and the average price target is 8.57 USD. This implies a price increase of 425.64% is expected in the next year compared to the current price of 1.63. Check the ADC THERAPEUTICS SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ADC THERAPEUTICS SA worth?

ADC THERAPEUTICS SA (ADCT) has a market capitalization of 157.60M USD. This makes ADCT a Micro Cap stock.


How many employees does ADC THERAPEUTICS SA have?

ADC THERAPEUTICS SA (ADCT) currently has 274 employees.


What are the support and resistance levels for ADC THERAPEUTICS SA (ADCT) stock?

ADC THERAPEUTICS SA (ADCT) has a support level at 1.51 and a resistance level at 1.75. Check the full technical report for a detailed analysis of ADCT support and resistance levels.


Is ADC THERAPEUTICS SA (ADCT) expected to grow?

The Revenue of ADC THERAPEUTICS SA (ADCT) is expected to grow by 6.71% in the next year. Check the estimates tab for more information on the ADCT EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ADC THERAPEUTICS SA (ADCT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ADC THERAPEUTICS SA (ADCT) stock pay dividends?

ADCT does not pay a dividend.


When does ADC THERAPEUTICS SA (ADCT) report earnings?

ADC THERAPEUTICS SA (ADCT) will report earnings on 2025-03-13, after the market close.


What is the Price/Earnings (PE) ratio of ADC THERAPEUTICS SA (ADCT)?

ADC THERAPEUTICS SA (ADCT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.39).


What is the Short Interest ratio of ADC THERAPEUTICS SA (ADCT) stock?

The outstanding short interest for ADC THERAPEUTICS SA (ADCT) is 6.73% of its float. Check the ownership tab for more information on the ADCT short interest.


ADCT Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ADCT Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ADCT. ADCT has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ADCT Financial Highlights

Over the last trailing twelve months ADCT reported a non-GAAP Earnings per Share(EPS) of -2.39. The EPS decreased by -8.64% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -105.18%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%27.59%
Sales Q2Q%27.4%
EPS 1Y (TTM)-8.64%
Revenue 1Y (TTM)0.75%

ADCT Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to ADCT. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of 40.62% and a revenue growth 6.71% for ADCT


Ownership
Inst Owners56.97%
Ins Owners5.49%
Short Float %6.73%
Short Ratio4.62
Analysts
Analysts84.62
Price Target8.57 (425.77%)
EPS Next Y40.62%
Revenue Next Year6.71%